Investment activity in the life sciences private-equity arena has become increasingly popular over the last few years, as the need for consolidation in an ever-changing and oftentimes volatile marketplace continues to increase. While the Specialty Pharmacy, Pharmaceutical and Biotech spaces are growing rapidly and present many opportunities for investment, these investments and transactions require high-level specialized industry knowledge that corporate transactional attorneys cannot provide.
Frier Levitt is able to identify issues and provide an independent viewpoint necessary to make intelligent and informed decisions for both buyers and sellers, all from a high-level healthcare legal perspective.
Frier Levitt’s Healthcare Investment Practice Group provides counsel to pharmacies and other life sciences organizations on an array of strategies aimed at expanding their footprint and enticing Private Equity investment, including:
Frier Levitt assists pharmacies and other life sciences organizations in preparing to enter the private entity marketplace through a variety of “go-to-market” strategies, offering intricate analysis of an organization’s business model from a regulatory perspective and utilizing a host of laws aimed at expanding business opportunities, including State and Federal Any Willing Provider laws, Prompt Payment laws, and reimbursement negotiation.
Frier Levitt works directly with a variety of pharmacy and other life sciences organizations regarding the many regulatory hurdles that challenge operations and potentially prevent growth, including:
Identifying the Ideal Private Equity Partner/Target Pharmacy:
Private Equity Transaction Services:
If you are a pharmacy or life sciences organization interested in learning more about Private Equity Investment, contact Frier Levitt today to speak to a member of our Healthcare Investment Practice Group.
Frier Levitt’s Healthcare Investment Practice Group provides a host of services to Mutual Funds, Hedge Funds, Venture Capital, and the Private Equity community looking to invest and understand regulatory risk in Specialty Pharmacy, Pharmaceutical, Biotech, and other public healthcare companies. Our clients include some of the largest financial institutions, publicly traded healthcare corporations, coalitions of healthcare providers, and entities involved in acquisitions valued in excess of $100 million.
Frier Levitt has extensive experience working directly with pharmacies and healthcare organizations in order to expand their business model in an effort to entice investment opportunities. Frier Levitt is able to offer intricate analysis of a company’s business model from a regulatory perspective and utilize a host of laws aimed at expanding business opportunities, including State and Federal Any Willing Provider laws, Prompt Payment laws, reimbursement negotiation, and access to limited drug networks.
We work directly with a variety of Specialty Pharmacy and other healthcare organizations regarding the many regulatory hurdles that challenge operations and potentially prevent growth, including:
If you are a Mutual Fund, Hedge Fund, Venture Capital, or Private Equity investor interested in learning more about investment in life sciences organizations, contact Frier Levitt today to speak to a member of our Healthcare Investment Practice Group.